Redcliffe Labs Divests Crysta IVF to Moon Care to Focus on Diagnostic

In a major move, Redcliffe Labs divests Crysta IVF to Moon Care, the healthcare arm of MMG Group, reinforcing its focus on diagnostics.

This Redcliffe Labs divests Crysta IVF deal highlights the company’s preventive-first strategy and sharper focus on expanding advanced diagnostic services across India.

Redcliffe Labs stated that the decision aligns with its long-term goal of strengthening its diagnostics network and improving access to preventive healthcare. Meanwhile, Crysta IVF is expected to scale further under Moon Care, which plans to enhance fertility care through technology and wider reach.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

Aditya Kandoi, founder & CEO, Redcliffe Labs, said: “Our priority has always been to build a strong, accessible diagnostics ecosystem rooted in preventive healthcare - with the goal of adding healthier years to people’s lives. This divestment allows us to sharpen that focus even further. What started as an Operate & Manage model in 2021 evolved into a scalable network of high-quality, self-owned centres, achieving profitability in a relatively short time.”

Sanjeev Agarwal, chairman, MMG Group, said: “Our focus will be on making fertility care even more accessible and deeply technology-driven. Crysta IVF has earned the trust of thousands of families, and we see a strong opportunity to expanding access to high-quality fertility treatments across the country while continuing to enhance patient experience and outcomes.”

Mohit Khullar managing director and leader - corporate finance, Alvarez & Marsal India noted strong investor confidence in the IVF segment and growth potential ahead.

The transition will remain seamless for patients, with existing teams continuing operations while Moon Care drives future expansion and innovation.